These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25332032)

  • 61. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
    Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
    J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community.
    Hughes K; Leggett B; Del Mar C; Croese J; Fairley S; Masson J; Aitken J; Clavarino A; Janda M; Stanton WR; Tong S; Newman B
    Aust N Z J Public Health; 2005 Aug; 29(4):358-64. PubMed ID: 16222934
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data.
    Tran B; Keating CL; Ananda SS; Kosmider S; Jones I; Croxford M; Field KM; Carter RC; Gibbs P
    Intern Med J; 2012 Jul; 42(7):794-800. PubMed ID: 21883782
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.
    Geraghty J; Butler P; Seaman H; Snowball J; Sarkar S; Blanks R; Halloran S; Bodger K; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2156-62. PubMed ID: 25225905
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
    Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Equity of colorectal cancer screening: cross-sectional analysis of National Bowel Cancer Screening Program data for South Australia.
    Ward PR; Javanparast S; Matt MA; Martini A; Tsourtos G; Cole S; Gill T; Aylward P; Baratiny G; Jiwa M; Misan G; Wilson C; Young G
    Aust N Z J Public Health; 2011 Feb; 35(1):61-5. PubMed ID: 21299702
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative effectiveness of screening strategies for colorectal cancer.
    Barzi A; Lenz HJ; Quinn DI; Sadeghi S
    Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy.
    Giorgi Rossi P; Vicentini M; Sacchettini C; Di Felice E; Caroli S; Ferrari F; Mangone L; Pezzarossi A; Roncaglia F; Campari C; Sassatelli R; Sacchero R; Sereni G; Paterlini L; Zappa M
    Am J Gastroenterol; 2015 Sep; 110(9):1359-66. PubMed ID: 26303133
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.
    Sharp L; Tilson L; Whyte S; Ceilleachair AO; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
    BMC Health Serv Res; 2013 Mar; 13():105. PubMed ID: 23510135
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
    Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
    J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.
    Greuter MJ; Demirel E; Lew JB; Berkhof J; Xu XM; Canfell K; Dekker E; Meijer GA; Coupé VM
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):135-44. PubMed ID: 26598535
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhancing bowel screening: Preventing colorectal cancer by flexible sigmoidoscopy in New Zealand.
    Cox B; Sneyd MJ; Hingston G; McBride D; Bagshaw PF
    Public Health; 2020 Feb; 179():27-37. PubMed ID: 31726398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.
    Heresbach D; Manfredi S; D'halluin PN; Bretagne JF; Branger B
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):427-33. PubMed ID: 16538116
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests.
    Stone CA; Carter RC; Vos T; John JS
    Aust N Z J Public Health; 2004 Jun; 28(3):273-82. PubMed ID: 15707175
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates.
    Zorzi M; Zappa M;
    Gut; 2020 Feb; 69(2):311-316. PubMed ID: 31040168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.